Skip to main content
SpringerLink
Log in

Adalimumab/certolizumab-pegol/infliximab

Psoriasis : case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • White B, et al. Vedolizumab resulted in resolution of anti-tumor necrosis factor psoriasis and sustained clinical and endoscopic remission of crohn's colitis. Inflammatory Bowel Diseases 22: S79 abstr. P230, Mar 2016. Available from: URL: http://doi.org/10.1097/01.MIB.0000480345.92088.58 [abstract] - USA

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Adalimumab/certolizumab-pegol/infliximab. Reactions Weekly 1595, 15 (2016). https://doi.org/10.1007/s40278-016-16047-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-016-16047-3

Search

Navigation